Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Investigative Site, Buffalo

Investigative Site, Elkin

Investigative Site, Gainesville

Investigative Site, Hollywood

Investigative Site, Miami

Investigative Site, Boca Raton

Investigative Site, Tampa

Investigative Site, Chattanooga

Investigative Site, Cincinnati

Investigative Site, Arlington Heights

Investigative Site, Rockford

Investigative Site, North Little Rock

Investigative Site, Oklahoma City

Investigative Site, Lake Jackson

Investigative Site, Colorado Springs

Investigative Site, Salt Lake City

Investigative Site, Tucson

Investigative Site, San Diego

Investigative Site, Riverside

Investigative Site, Orange

Investigative Site, Sacramento

Investigative Site, Portland

Investigative Site, Bellevue

Investigative Site, Seattle

Investigative Site, Everett

Investigative Site, Monroe

Investigative Site, Jacksonville

Investigative Site, Los Angeles

Investigative Site, Bristol

Investigative Site, Hartford

Investigative Site, New Smyrna Beach

Investigative Site, Boston

Investigative Site, Wellesley Hills

Investigative Site, Mexico

Investigative Site, Great Neck

Investigative Site, San Antonio

Investigative Site, Chesapeake

Investigative Site, Calgary

Investigative Site, St. John's

Investigative Site, Hamilton

Investigative Site, Montreal

Investigative Site, Québec

Investigative Site, Sherbrooke